HLB Innovation Unveils Preclinical Results of Verismo's Solid Tumor CAR-T
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.3× normal (5 trading days)
Preclinical solid tumor CAR-T data at a conference; early-stage, no revenue size given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.